针对癌基因驱动的非小细胞肺癌老年患者的向治疗:SIOG专家组的建议
L Decoster1, D R Camidge2, J A Fletcher3
1Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Department of Medical Oncology, Translational Oncology Research Center (TORC), Team Laboratory for Medical and Molecular Oncology (LMMO), Laarbeeklaan 101 1090 Brussels, Belgium.
患有晚期非小细胞肺癌 (NSCLC) 的老年人 (70岁以上) 从向治疗中受益,但数据有限. 本综述提供了专家建议,以治疗这种人群与瘤基因驱动的NSCLC.
科学领域:
- 老年瘤学 老年瘤学
- 胸部瘤学 胸部瘤学
- 药物基因组学 药物基因组学
背景情况:
- 肺癌不成比例地影响到老年人 (≥70岁).
- 对老年患者的治疗决定是复杂的,因为在临床试验中异质性和代表性不足.
- 向疗法已经改变了高级非小细胞肺癌 (NSCLC) 管理.
研究的目的:
- 审查针对性疗法的疗效和耐受性,在老年人 (≥70岁) 癌基因驱动的NSCLC.
- 为这种特定患者群体的治疗提供专家建议.
- 为了解决NSCLC临床试验中老年人群的稀疏数据.
主要方法:
- 在70岁及以上的患者中针对癌基因驱动的NSCLC的向疗法的系统性文献综述.
- 国际老年瘤学会 (SIOG) NSCLC工作组的专家共识和准则制定.
- 对老年人群中疗效,安全性和以患者为中心的结果的现有数据的分析.
主要成果:
- 向治疗可显著改善NSCLC患者的预后和生活质量.
- 关于这些药物的特定疗效和耐受性,在70岁及以上的患者中存在有限的数据.
- 老年患者面临着独特的挑战,包括并发症,多药性和脆弱性.
结论:
- 针对性疗法对于癌基因驱动的NSCLC至关重要,但它们在老年人中的使用需要仔细考虑.
- 需要专家建议来指导NSCLC老年患者的临床决策.
- 进一步的研究对于解决接受向癌症治疗的老年人群数据缺口至关重要.
更多相关视频
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy